Since PRG2 plays a tumor suppressor function, and PRG4 shows an anti-inflammatory role [25, 26], the downregulation of these proteoglycans in the cancerous ECM have been additional investigated by IHC analysis in paired samples (Fig. 3), and confirm the results obtained from the proteomics analysis. The gene discussed is PRG2; the disease is neoplasm.